TP53 and ovarian carcinoma: To further confirm that ME can enhance the cisplatin sensitivity of chemoresistant ovarian cancer cells, the expression of p-p53 in A2780/CDDP cells was analyzed using immunofluorescent staining and was shown to be significantly increased with the combination of ME and cisplatin and was higher than ME or cisplatin treatment alone (Figure 1(e)).